BioDrugs

, Volume 23, Issue 6, pp 377–389

Sunitinib

A Multitargeted Receptor Tyrosine Kinase Inhibitor in the Era of Molecular Cancer Therapies
Review Article

Abstract

Sunitinib is an oral oxindole multitargeted kinase inhibitor that inhibits certain receptor tyrosine kinases (RTKs). These include vascular endothelial growth factor receptors (VEGFR type 1 and 2), platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), stem cell factor receptor (KIT), FMS-like tyrosine kinase-3 (FLT3), glial cell-line derived neurotrophic factor receptor (RET) and the receptor of macrophagecolony stimulating factor (CSF1R). Examination of the antitumor effect of sunitinib in a variety of cell lines in vitro suggested an antiproliferative activity that is dependent on the presence of constitutively active RTK targets. The use of sunitinib as first-line therapy in advanced renal cell carcinoma (RCC) has improved the overall survival compared with that observed after cytokine therapy, while its administration in patients with gastrointestinal stromal tumors (GISTs) after progression or intolerance to imatinib achieved an objective response of 7%. Sunitinib is currently approved for the treatment of GISTs in this setting, and as first-line therapy for the treatment of advanced RCC. The relatively long half-life of sunitinib and its major metabolite allow for a once-daily dosing schedule. An interesting antitumor activity of sunitinib was reported in phase II studies of patients with a variety of malignancies, such as hepatocellular cancer, pancreatic neuroendocrine tumors, and non-small cell lung cancer; results of phase III studies are urgently anticipated. Fatigue is one of the most common adverse effects of sunitinib, as 50–70% of patients with advanced RCC and GIST complained of this adverse effect. Other adverse effects are diarrhea, anorexia, nausea and vomiting, oral changes and bleeding events. Most toxicities are reversible and should not result in discontinuation of sunitinib. If necessary, dose adjustments or interruptions should be made. Hypothyroidism has been described in the first 2 weeks of sunitinib therapy and its incidence increases progressively with the duration of therapy. Sunitinib may exert its hypertensive activity through a direct effect on the vasculature, while its most important cardiac adverse effect is left ventricular dysfunction. A variety of skin adverse effects have been described with the use of sunitinib such as hand-foot syndrome, yellow discoloration of the skin, dry skin, subungual splinter hemorrhages, acral erythema, and generalized skin rashes. Administration of sunitinib in the adjuvant and neoadjuvant setting of patients with RCC and of its combination with chemotherapy and other targeted therapies are currently under intense investigation.

References

  1. 1.
    Syrigos KN, Harrington KJ. Targeted therapy for cancer. Oxford: Oxford University Press, 2002 OctGoogle Scholar
  2. 2.
    Papaetis GS, Roussos C, Syrigos KN. Targeted therapies for non-small cell lung cancer. Curr Pharm Des 2007; 13: 2810–31PubMedCrossRefGoogle Scholar
  3. 3.
    Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol 2005; 45: 357–84CrossRefGoogle Scholar
  4. 4.
    Charpidou A, Blatza D, Anagnostou E, et al. Review: EGFR mutations in non-small cell lung cancer — clinical implications. In Vivo 2008; 22: 529–36PubMedGoogle Scholar
  5. 5.
    Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6: 273–86PubMedCrossRefGoogle Scholar
  6. 6.
    Folkman J. Tumour angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182–6PubMedCrossRefGoogle Scholar
  7. 7.
    Bergers G, Benjamin LE. Tumourigenesis and the angiogenic switch. Cancer Nat Rev 2003; 3: 401–10CrossRefGoogle Scholar
  8. 8.
    Senger Dr, Galli Sj, Drovak AM, et al. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983–5PubMedCrossRefGoogle Scholar
  9. 9.
    Drovak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am JPathol 1995; 146: 1029–39Google Scholar
  10. 10.
    Karayiannakis AJ, Syrigos KN, Polychronidis A, et al. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumour surgery. Ann Surg 2002; 236: 37–42PubMedCrossRefGoogle Scholar
  11. 11.
    Karayiannakis AJ, Bolanaki H, Syrigos KN, et al. Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 2003; 194: 119–24PubMedCrossRefGoogle Scholar
  12. 12.
    Fong GH, Rossant J, Gertsenstein M, et al. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 1995; 376: 66–70PubMedCrossRefGoogle Scholar
  13. 13.
    Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999; 79: 1283–316PubMedGoogle Scholar
  14. 14.
    Bhardwaj B, Klassen J, Cossette N, et al. Localization of platelet-derived growth factor b receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 1996; 2: 773–82PubMedGoogle Scholar
  15. 15.
    Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004; 18: 338–40PubMedGoogle Scholar
  16. 16.
    Papaetis GS, Syrigos KN. Targeted therapy for gastrointestinal stromal tumors: Current status and future perspectives. Cancer Metastasis Rev. In pressGoogle Scholar
  17. 17.
    Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327–37PubMedGoogle Scholar
  18. 18.
    Papaetis GS, Karapanagiotou LM, Pandha H, et al. Targeted therapy for advanced renal cell cancer: cytokines and beyond. Curr Pharm Des 2008; 14: 2229–51PubMedCrossRefGoogle Scholar
  19. 19.
    Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007; 13: 1367–73PubMedCrossRefGoogle Scholar
  20. 20.
    Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU 11248 against gastrointestinal stromal tumor mutants refractory to imatinib me-sylate. Clin Cancer Res 2006; 12: 2622–7PubMedCrossRefGoogle Scholar
  21. 21.
    O'Farrell AM, Abrams TJ, Yuen HA, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 597–3605CrossRefGoogle Scholar
  22. 22.
    Yee KW, Schittenhelm M, O'Farrell AM, et al. Synergistic effect of SU 11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. Blood 2004; 104: 4202–9PubMedCrossRefGoogle Scholar
  23. 23.
    Christensen JG. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007; 18Suppl. 10: 3–10CrossRefGoogle Scholar
  24. 24.
    Abrams T, Lee LB, Murray LJ, et al. SU 11248 inhibits KIT and platelet derived growth factor receptor-β in preclinical models of human small cell lung cancer. Mol Cancer Ther 2003; 2: 471–8PubMedGoogle Scholar
  25. 25.
    Schmidt CM, Settle SL, Keene JL, et al. Characterization of spontaneous metastasis in an aggressive breast carcinoma model using flow cytometry. Clin Exp Metastasis 1999; 17: 537–44PubMedCrossRefGoogle Scholar
  26. 26.
    Murray LJ, Abrams TJ, Long KR, et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003; 20: 757–66PubMedCrossRefGoogle Scholar
  27. 27.
    Osusky KL, Hallahan DE, Fu A, et al. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis 2004; 7: 225–33PubMedCrossRefGoogle Scholar
  28. 28.
    Czabanka M, Vinci M, Heppner F, et al. Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int J Cancer 2009; 124: 1293–300PubMedCrossRefGoogle Scholar
  29. 29.
    Baratte S, Sarati S, Frigerio E, et al. Quantitation of SU1 1248, an oral multitarget tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semiautomated liquid-liquid extraction. J Chromatogr A 2004; 1024: 87–94PubMedCrossRefGoogle Scholar
  30. 30.
    Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006; 24: 25–35PubMedCrossRefGoogle Scholar
  31. 31.
    Grandinetti CA, Goldspiel BR. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer. Pharmacotherapy 2007; 27: 1125–44PubMedCrossRefGoogle Scholar
  32. 32.
    Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006; 17: 353–8PubMedCrossRefGoogle Scholar
  33. 33.
    Hiles JJ, Kolesar JM. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 2008; 65: 123–31PubMedCrossRefGoogle Scholar
  34. 34.
    Washington C, Eli M, Bello C. The effect of ketoconazole (KETO), a potent CYP3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects [abstract 553]. Proc Am Soc Clin Oncol 2003; 22: 180Google Scholar
  35. 35.
    Bello C, Houk B, Sherman L. Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers [abstract]. J Clin Oncol 2005; 23Suppl. 16S: 3078Google Scholar
  36. 36.
    Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol 2001; 166: 1611–23PubMedCrossRefGoogle Scholar
  37. 37.
    Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 2005; 31: 536–45PubMedCrossRefGoogle Scholar
  38. 38.
    Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425Google Scholar
  39. 39.
    Bukowski RM. Natural history and therapy of metastatic renal carcinoma: the role of interleukin-2. Cancer 1997; 80: 1198–220PubMedCrossRefGoogle Scholar
  40. 40.
    Yao M, Yoshida M, Kishida T, et al. VHL tumor suppressor gene alterations associated with good prognosis in sporadic clear-cell renal carcinoma. J Natl Cancer Inst 2002; 94: 1569–75PubMedCrossRefGoogle Scholar
  41. 41.
    Zimmer M, Doucette D, Siddiqui N, et al. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors. Mol Cancer Res 2004; 2: 89–95PubMedGoogle Scholar
  42. 42.
    Rosen L, Mulay M, Long J. Phase I trial of SU11248, a novel tyrosine kinase inhibitor in advanced solid tumors [abstract]. Proc Am Soc Clin Oncol 2003; 22: 765aGoogle Scholar
  43. 43.
    O'Farell AM, Foran JM, Fiedler W, et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 2003; 9: 5465–76Google Scholar
  44. 44.
    Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190–5PubMedCrossRefGoogle Scholar
  45. 45.
    Motzer RJ, Rini BI, Michaelson MD, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC) [abstract 4508]. Proc Am Soc Clin Oncol 2005; 23: 380sGoogle Scholar
  46. 46.
    Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006; 24: 16–24PubMedCrossRefGoogle Scholar
  47. 47.
    Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006; 295: 2516–24PubMedCrossRefGoogle Scholar
  48. 48.
    Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115–24PubMedCrossRefGoogle Scholar
  49. 49.
    Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454–63PubMedCrossRefGoogle Scholar
  50. 50.
    Figlin RA, Hutson TE, Tomczak P. Overall survival with sunitinib vs. interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC) [abstract]. J Clin Oncol 2008; 26 Suppl.: 5024Google Scholar
  51. 51.
    Kollmannsberger CK, Heng DY, Murray N, et al. A population based study evaluating metastatic renal cell cancer (mRCC) patients treated with interferon (IFN) alone, first-line IFN then second-line sunitinib, or sunitinib alone [abstract]. J Clin Oncol 2007; 25Suppl. 18: 15572Google Scholar
  52. 52.
    Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009; 115: 776–83PubMedCrossRefGoogle Scholar
  53. 53.
    Rini BI, George DJ, Michaelson MD. Efficacy and safety of sunitinib malate (SU 11248) in bevacizumab-refractory metastatic renal cell carcinoma [abstract 4522]. Proc Am Soc Clin Oncol 2006; 24: 222sGoogle Scholar
  54. 54.
    Redman BG, Hudes GR, Kim ST, et al. Sunitinb in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC): updated results from a phase I/II study [abstract]. J Clin Oncol 2008; 26 Suppl.: 16014Google Scholar
  55. 55.
    Ryan CW, Curti BD, Pattee KJ, et al. A dose-escalation phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). 2008 Genitourinary Cancers Symposium; 2008 Feb 14-16; San Francisco (CA)Google Scholar
  56. 56.
    Vance V, Amato RJ, Jac J, et al. Phase I study of PEG-intron, sunitinib and tarceva in patients with metastatic renal cell carcer (MRCC) [abstract]. J Clin Oncol 2008; 26 Suppl.: 14659Google Scholar
  57. 57.
    Pandya SS, Mier JW, Cho D, et al. The role of adding gemcitabine at time of sunitinib resistance in patients with metastatic renal cell cancer. 2008 Genitourinary Cancers Symposium; 2008 Feb 14–16; San Francisco (CA)Google Scholar
  58. 58.
    Patel PH, Senico PL, Curiel RE, et al. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009; 7: 24–7PubMedCrossRefGoogle Scholar
  59. 59.
    Feldman DR, Baum MS, Ginsberg MS, et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(9): 1432–9PubMedCrossRefGoogle Scholar
  60. 60.
    Motzer RJ, Hudes G, Wilding G, et al. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 2009; 7: 28–33PubMedCrossRefGoogle Scholar
  61. 61.
    Haas NB, Uzzo RG. The ASSURE trial-adjuvant sunitinib vs. sorafenib vs. placebo in patients with recsected renal cell carcinoma. US Renal GenitoUrinary Dis 2006; 6: 54–6Google Scholar
  62. 62.
    Biswas S, Kelly J, Eisen T. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 2009; 14: 52–9PubMedCrossRefGoogle Scholar
  63. 63.
    Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438: 1–12PubMedCrossRefGoogle Scholar
  64. 64.
    Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577–80PubMedCrossRefGoogle Scholar
  65. 65.
    Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299: 708–10PubMedCrossRefGoogle Scholar
  66. 66.
    Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 2006; 59: 557–63PubMedCrossRefGoogle Scholar
  67. 67.
    Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation of Treatment and Research of Cancer — Italian Sarcoma Group — Australasian Gastrointestinal Trials Group Study. J Clin Oncol 2005; 23: 5795–804PubMedCrossRefGoogle Scholar
  68. 68.
    Wardelmann E, Merkelbach-Bruse S, Pauls K, et al. Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 2006; 12: 1743–9PubMedCrossRefGoogle Scholar
  69. 69.
    Heinrichm MC, Maki R, Corless CL. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFR mutation status. 42nd Annual Meeting of the American Society for Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)Google Scholar
  70. 70.
    Morgan JA, Demetri GD, Fletcher JA. Durable responses to SU 11248 (sunitinib malate) are observed across all genotypes of imatinib mesylate-resistant GIST. 17th International Congress on Anti Cancer Treatment; 2006 Jan 30–Feb 2; ParisGoogle Scholar
  71. 71.
    Maki RG, Fletcher JA, Heinrich MC. SU11248 in patients with imatinib-resistant GIST: results from a continuation trial. American Society of Clinical Oncology. 41st Annual Meeting; 2005 May 13–17; Orlando (FL)Google Scholar
  72. 72.
    Liegl B, Fletcher JA, Corless CL. Correlation between KIT mutations and sunitinib (SU) resistance in GIST [abstract 92]. Program and abstracts of the 2008 American Society of Clinical Oncology Gastrointestinal Cancer Symposium; 2008 Jan 25–27: Orlando (FL)Google Scholar
  73. 73.
    Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumor after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329–38PubMedCrossRefGoogle Scholar
  74. 74.
    Judson I, Casali P, Garret C. Updated results from a phase III trial of sunitinib in advanced gastrointestinal stromal tumors (GIST) [abstract]. Ann Oncol 2006; 17 Suppl. 9: ix62Google Scholar
  75. 75.
    Casali PG, Garret CR, Blackstein ME. Updated results from a phase III trial of sunitinib in GIST patients (pts) for whom imatinib (IM) therapy has failed due to resistance or intolerance. 42nd Annual Meeting of the American Society for Clinical Oncology; 2006 Jun 2–6; Atlanta (GA)Google Scholar
  76. 76.
    George S, Blay JY, Casali PG. Continuous daily dosing (CDD) of sunitinib (SU) in pts with advanced GIST: updated efficacy, safety, PK and phar-macodynamic analysis [abstract 10554]. J Clin Oncol 2008; 26: 1530Google Scholar
  77. 77.
    Zhu AX. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 2006; 11: 790–800PubMedCrossRefGoogle Scholar
  78. 78.
    Yao DF, Wu XH, Zhu Y, et al. Quantitative analysis of vascular endothelial growth factor, microvascular density and their clinopathologic features in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2005; 4: 220–6PubMedGoogle Scholar
  79. 79.
    Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor and angiogenin in patients with respectable hepatocellular carcinoma after surgery. Ann Surg Oncol 2003; 10: 355–62PubMedCrossRefGoogle Scholar
  80. 80.
    Zhang T, Sun HC, Xu Y, et al. Overexpression of platelet-derived growth factor receptor-α in endothelial cells of hepatocellular carcinoma associated with high metastatic poptential. Clin Cancer Res 2005; 11: 8557–63PubMedCrossRefGoogle Scholar
  81. 81.
    Zhu AX, Sahani DV, di Tomaso E, et al. Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): insights from a multidisciplinary phase II study. J Clin Oncol (Meeting Abstracts) 2008; 26: 4521Google Scholar
  82. 82.
    Faivre S, DePrimo S, Cheng AL. Correlation of outcome and tumor imaging parameters with circulating biomarkers of sunitinib malate in patients with unresectable hepatocellular carcinoma. 33rd ESMO Congress; 2008 Sep 12-16; StockholmGoogle Scholar
  83. 83.
    La Rossa S, Uccella S, Finzi G, et al. Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic feature. Hum Pathol 2003; 34: 18–27CrossRefGoogle Scholar
  84. 84.
    Chaudhry A, Papanicolaou V, Oberg K, et al. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res 1992; 52: 1006–12PubMedGoogle Scholar
  85. 85.
    Koch CA, Gimm O, Vortmeyer AO, et al. Does the expression of c-kit (CD-117) in neuroendocrine tumors represent a target of therapy? Ann N Y Acad Sci 2006; 1073: 517–26PubMedCrossRefGoogle Scholar
  86. 86.
    Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neurondocrine tumors. J Clin Oncol 2008; 26: 3403–10PubMedCrossRefGoogle Scholar
  87. 87.
    Bajetta E, Guadalupi V, Procopio G. Activity of sunitinib in patients with advanced neurondocrine tumors. J Clin Oncol 2009; 27: 319–20; author reply 320PubMedCrossRefGoogle Scholar
  88. 88.
    Potapova O, Laird AD, Nannini MA, et al. Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther 2006; 5: 1280–9PubMedCrossRefGoogle Scholar
  89. 89.
    Socinski MA, Novello S, Sanchez JM. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): preliminary results of a multicenter phase II trial. J Clin Oncol 2006 ASCO Ann Meet Proc Pt I 2006; 24(18 Suppl. Jun 20): 7001Google Scholar
  90. 90.
    Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008; 26: 650–6PubMedCrossRefGoogle Scholar
  91. 91.
    Brahmer JR, Govindan R, Novello S. Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): results from a phase II study. J Clin Oncol 2006 ASCO Ann Meet Proc Pt I 2006; 25(18 Suppl. Jun 20): 7542Google Scholar
  92. 92.
    Gridelli C, Maione P, Rossi A, et al. New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Rev Anticancer Ther 2009; 9: 115–24PubMedCrossRefGoogle Scholar
  93. 93.
    Jennbacken K, Vallbo C, Wang W, et al. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 2005; 65: 110–6PubMedCrossRefGoogle Scholar
  94. 94.
    George DJ, Halabi S, Shepard TF, et al. Prognostic significance of vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin Cancer Res 2001; 7: 1932–6PubMedGoogle Scholar
  95. 95.
    Hofer MD, Fecko A, Shen R, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 2004; 6: 503–12PubMedCrossRefGoogle Scholar
  96. 96.
    Cumashi A, Tinari N, Rossi C, et al. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts. Cancer Lett 2008; 270(2): 229–33PubMedCrossRefGoogle Scholar
  97. 97.
    Guerin O, Formento P, Lo Nigro C, et al. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel: a new therapeutic perspective in hormone refractory prostate cancer. J Cancer Res Clin Oncol 2008; 134: 51–7PubMedCrossRefGoogle Scholar
  98. 98.
    Sonpavde G, Hutson TE, Berry WR, et al. Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. Clin Genitourin Cancer 2008; 6: 134–7PubMedCrossRefGoogle Scholar
  99. 99.
    Saltz LB, Rosen LS, Marshall JL, et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol 2007; 25: 4793–9PubMedCrossRefGoogle Scholar
  100. 100.
    Fenner MH, Beutel G, Grunwald V. Targeted therapies for patients with germ cell tumors. Expert Opin Investig Drugs 2008; 17: 511–22PubMedCrossRefGoogle Scholar
  101. 101.
    Dawson SJ, Conus NM, Toner GC, et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008; 9: 547–52CrossRefGoogle Scholar
  102. 102.
    Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008; 26: 1810–6PubMedCrossRefGoogle Scholar
  103. 103.
    Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006; 145: 660–4PubMedGoogle Scholar
  104. 104.
    Rini BI, Tamaskar I, Shaheen P, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007; 99: 81–3PubMedCrossRefGoogle Scholar
  105. 105.
    Mannavola D, Coco P, Vannucchi G, et al. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab 2007; 92: 3531–4PubMedCrossRefGoogle Scholar
  106. 106.
    Wolter P, Stefan C, Decallonne B. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer [abstract]. J Clin Oncol 2008; 26 Suppl.: 5126CrossRefGoogle Scholar
  107. 107.
    Sica DA. Angiogenesis inhibitors and hypertension: an emerging issue. J Clin Oncol 2006; 24: 1329–31PubMedCrossRefGoogle Scholar
  108. 108.
    Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363–9PubMedCrossRefGoogle Scholar
  109. 109.
    Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72PubMedCrossRefGoogle Scholar
  110. 110.
    Izzedine H, Ederhy S, Goldwasser F, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20(5): 807–15PubMedCrossRefGoogle Scholar
  111. 111.
    Kollmannsberger C, Soulieres D, Wong R, et al. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 2007; 1(2 Suppl.): S41–54PubMedGoogle Scholar
  112. 112.
    Hutson TE, Figlin RA, Kuhn JG, et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084–96PubMedCrossRefGoogle Scholar
  113. 113.
    Telli ML, Witteles RM, Fisher GA. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. 2008 American Society of Clinical Oncology Genitourinary Cancers Symposium; 2008 Feb 14–16; San Francisco (CA)Google Scholar
  114. 114.
    Schmidinger M, Zielinski CC, Vogl UM, et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008; 26: 5204–12PubMedCrossRefGoogle Scholar
  115. 115.
    Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011–9PubMedCrossRefGoogle Scholar
  116. 116.
    Chu D, Lacouture ME, Weiner M, et al. Risk of hand-foot skin reaction with multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitour Cancer 2009; 7: 11–9CrossRefGoogle Scholar
  117. 117.
    Botchkareva NV, Khlgatian M, Longley BJ, et al. SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit. FASEB J 2001; 15: 645–58PubMedCrossRefGoogle Scholar
  118. 118.
    Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 917–30PubMedCrossRefGoogle Scholar
  119. 119.
    Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib [letter]. J Clin Oncol 2007; 25: 3559PubMedCrossRefGoogle Scholar
  120. 120.
    Michael A, Syrigos K, Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis 2009; 12(1): 13–6PubMedCrossRefGoogle Scholar
  121. 121.
    Syrigos KN, Zalonis A, Kotteas E, et al. Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev 2008; 27: 273–88PubMedCrossRefGoogle Scholar
  122. 122.
    Strimpakos AS, Karapanagiotou EM, Saif WM, et al. The role of m TOR in the management of solid tumors: an overview. Cancer Treat Rev 2009; 35(2): 148–59PubMedCrossRefGoogle Scholar
  123. 123.
    Strimpakos A, Saif MW, Syrigos KN. Pancreatic cancer: from molecular pathogenesis to targeted therapy. Cancer Metastasis Rev 2008; 27: 495–522PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  1. 1.Oncology Unit, Third Department of MedicineAthens University School of MedicineAthensGreece

Personalised recommendations